{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:14:56Z","timestamp":1778858096993,"version":"3.51.4"},"reference-count":6,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,11,25]],"date-time":"2010-11-25T00:00:00Z","timestamp":1290643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Approximately 20\u201330% of patients with psoriasis treated with anti\u2010tumour necrosis factor \u03b1 (TNF\u03b1) agents will discontinue treatment within 2\u2003years due to loss of efficacy or side\u2010effects. Switching to another anti\u2010TNF\u03b1 agent produces clinical responses inferior to previously untreated patients. Ustekinumab binds to the p40 subunit of interleukin (IL)\u201012 and IL\u201023 and provides a mechanism of action independent of TNF\u03b1.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To investigate the efficacy of ustekinumab in a clinical practice setting and to compare treatment responses to ustekinumab in patients previously treated with TNF\u03b1 inhibitors and anti\u2010TNF\u03b1\u2010na\u00efve patients.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Patients receiving either ustekinumab (<jats:italic>n<\/jats:italic>\u2003=\u200371) or the subcutaneous TNF\u03b1 inhibitors adalimumab or etanercept (<jats:italic>n<\/jats:italic>\u2003=\u2003108) were identified through the registry of psoriasis patients in our Institutions. Efficacy effect outcome was a 75% improvement in the psoriasis area severity index (PASI75). Kaplan\u2013Meier statistics evaluated the adherence to the treatments expressed as drug survival rate.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> PASI75 was achieved in 80% of the ustekinumab\u2010treated patients after a median time of 112\u2003days. There was no difference in efficacy in anti\u2010TNF\u03b1\u2010na\u00efve patients compared with anti\u2010TNF\u03b1 unresponsive patients. Patients treated with ustekinumab showed a superior adherence to treatment in comparison with adalimumab and etanercept.<\/jats:p><jats:p><jats:bold>Limitations\u2002<\/jats:bold> Patients were non\u2010randomly assigned to treatment, which potentially may lead to biases. Observation time was short (1\u2003year).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> In clinical practice, the short\u2010term efficacy and patient adherence to ustekinumab are excellent and comparable to the data obtained in clinical trials. Lack of response to previous anti\u2010TNF treatment does not impair clinical response to ustekinumab.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2010.03914.x","type":"journal-article","created":{"date-parts":[[2010,11,26]],"date-time":"2010-11-26T03:24:23Z","timestamp":1290741863000},"page":"1037-1040","source":"Crossref","is-referenced-by-count":61,"title":["Responses to ustekinumab in the anti\u2010TNF agent\u2010na\u00efve vs. anti\u2010TNF agent\u2010exposed patients with psoriasis vulgaris"],"prefix":"10.1111","volume":"25","author":[{"given":"A.","family":"Clemmensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Spon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Zachariae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810652"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09669.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken034"},{"key":"e_1_2_5_7_2","article-title":"Responses to adalimumab in psoriasis patients previously treated with anti\u2010tumor necrosis factor agents: subanalysis of BELIEVE","volume":"62","author":"Orthonne J\u2010P","year":"2010","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2010.03914.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2010.03914.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:24:10Z","timestamp":1697387050000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2010.03914.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,25]]},"references-count":6,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1468-3083.2010.03914.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03914.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,25]]}}}